This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MTX110

Midatech Pharma PLC

Description: Midatech is developing targeted cancer therapies by combining chemotherapeutic medicines with tumour-targeting molecules on the same GNP-based conjugate. Midatech has demonstrated the ability of GNPs and conjugates to cross the intact blood brain barrier in vitro and in vivo. A program is now underway, in collaboration with the Dana Farber Cancer Institute, to evaluate GNP conjugates with key chemotherapeutic agents used for the treatment of glioblastomas.


MTX110 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug